BAWEI
837023
XI'AN WONDER
836419
Jiangsu Tiangong Technology
920068
4
Fujian Green Pine
300132
5
Yili Chuanning Biotechnology
301301
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -4.20%2.1B | -1.08%6.34B | -2.23%4.79B | 2.39%3.69B | 0.93%2.19B | 9.42%6.4B | 11.14%4.9B | 13.60%3.6B | 8.34%2.17B | 5.72%5.85B |
Operating revenue | -4.11%2.08B | -0.86%6.25B | -2.16%4.72B | 2.48%3.64B | 0.95%2.17B | 9.26%6.3B | 10.96%4.83B | 13.46%3.56B | 8.23%2.15B | 6.48%5.77B |
Other operating revenue | ---- | -22.35%60.34M | ---- | -35.34%33.1M | ---- | 57.43%77.71M | ---- | 131.18%51.19M | ---- | -1.32%49.36M |
Interest income | -11.87%21.39M | -14.59%87.47M | -7.05%67.52M | -4.32%46.51M | -0.46%24.27M | 20.40%102.42M | 24.38%72.64M | 24.96%48.61M | 19.10%24.38M | -28.80%85.07M |
Total operating cost | -3.70%1.97B | -1.29%6.27B | -3.86%4.59B | 1.82%3.47B | -2.51%2.04B | 9.08%6.35B | 11.88%4.77B | 12.58%3.41B | 9.01%2.09B | 3.28%5.82B |
Operating cost | -3.44%1.8B | -0.49%5.37B | -2.90%3.93B | 2.87%3.03B | 0.60%1.86B | 7.64%5.4B | 10.58%4.05B | 12.97%2.95B | 9.00%1.85B | 8.99%5.01B |
Operating tax surcharges | -5.86%6.71M | 1.40%24.01M | 3.71%17.95M | 7.15%12.88M | 16.01%7.13M | -6.54%23.68M | 10.04%17.31M | 7.27%12.02M | -11.96%6.14M | -5.33%25.34M |
Operating expense | 0.11%58.07M | -3.31%196.55M | -2.84%180.75M | -8.84%114.19M | 28.22%58.01M | 1.90%203.29M | 6.04%186.04M | 7.21%125.27M | 3.97%45.24M | -6.11%199.5M |
Administration expense | -8.66%73.18M | -1.03%511.19M | -18.48%313.93M | -6.14%220.73M | -27.39%80.12M | 32.09%516.51M | 18.71%385.08M | 18.79%235.16M | 22.13%110.35M | -12.51%391.03M |
Financial expense | -13.48%28.37M | -21.20%162.72M | 6.59%143.7M | 2.44%85.08M | -58.95%32.79M | 9.36%206.5M | 52.41%134.81M | -5.38%83.05M | -1.07%79.87M | -45.68%188.83M |
-Interest expense (Financial expense) | -18.62%55.71M | -12.44%258.02M | -16.10%196.47M | -18.34%131.85M | -14.01%68.46M | -9.74%294.69M | -4.67%234.17M | -0.48%161.46M | 0.89%79.61M | -3.83%326.5M |
-Interest Income (Financial expense) | 11.46%-29.57M | -10.99%-74.34M | -14.51%-67.81M | -31.71%-38.48M | -89.14%-33.4M | -145.51%-66.98M | -175.42%-59.22M | -153.17%-29.21M | -374.61%-17.66M | -30.67%-27.28M |
Research and development | --231.13K | 2.11%457.55K | -10.91%231.13K | -10.91%231.13K | ---- | 6.74%448.11K | --259.43K | --259.43K | ---- | 48.33%419.81K |
Credit Impairment Loss | 5.29%-2.74M | 94.34%-1.56M | -48.02%2.39M | -191.38%-2.04M | -77.08%-2.89M | 69.23%-27.54M | 249.61%4.6M | 232.61%2.23M | 23.05%-1.63M | -149.84%-89.51M |
Asset Impairment Loss | ---- | 87.46%-53.12K | ---- | ---- | ---- | 94.51%-423.46K | ---- | ---- | ---- | -311.67%-7.72M |
Other net revenue | 1,417.38%149.25M | 3.93%360.08M | -38.76%174.32M | -76.41%104.28M | -104.24%-11.33M | 203.66%346.45M | 290.30%284.62M | 350.27%442.08M | 177.00%267.3M | -157.10%-334.21M |
Fair value change income | 327.92%11.87M | 107.18%24.53M | 87.19%-22.74M | 96.74%-4.99M | 86.57%-5.21M | 56.41%-341.48M | 12.95%-177.62M | -42.38%-152.94M | 75.67%-38.79M | -923.19%-783.43M |
Invest income | 1,401.75%134.66M | -55.76%292.37M | -63.03%161.06M | -84.66%88.65M | -103.44%-10.34M | 36.27%660.92M | 1,249.46%435.7M | 841.77%577.77M | 258.21%300.44M | -26.89%485M |
-Including: Investment income associates | 592.30%122.88M | -49.28%190.43M | -76.87%82.13M | -94.74%28.39M | -108.84%-24.96M | 396.76%375.49M | 827.86%355.04M | 543.94%539.52M | 242.51%282.42M | -84.00%75.59M |
Asset deal income | -81.69%13.34K | -27.97%11.99M | -142.16%-169.82K | -145.22%-182.76K | 1,352.74%72.82K | -32.66%16.65M | 125.38%402.83K | 125.51%404.17K | --5.01K | 1,995.90%24.72M |
Other revenue | -22.66%5.45M | -14.44%32.8M | 56.85%33.79M | 56.22%22.84M | -3.26%7.04M | 4.37%38.33M | -20.73%21.54M | 19.39%14.62M | 67.94%7.28M | 5.05%36.73M |
Operating profit | 104.51%282.23M | 6.50%429.06M | -8.61%376.63M | -48.97%326.56M | -59.86%138M | 234.05%402.88M | 6,569.92%412.1M | 2,268.04%639.99M | 229.89%343.83M | -161.70%-300.54M |
Add:Non operating Income | -2.18%668.77K | 851.16%13.37M | -91.14%1.61M | -66.09%759.66K | -45.76%683.67K | -70.77%1.41M | 593.21%18.16M | 168.57%2.24M | 159.21%1.26M | -45.48%4.81M |
Less:Non operating expense | 49.69%450.02K | 447.47%7.72M | 202.65%749.95K | 271.04%703.38K | 152.57%300.64K | -62.48%1.41M | -65.25%247.79K | 154.68%189.57K | 100.91%119.03K | 87.02%3.76M |
Total profit | 104.11%282.45M | 7.90%434.71M | -12.21%377.48M | -49.13%326.62M | -59.89%138.38M | 234.52%402.88M | 9,734.82%430.01M | 2,332.44%642.04M | 230.53%344.97M | -160.63%-299.49M |
Less:Income tax cost | -22.46%42.08M | 7.10%106.29M | 56.78%97.43M | 32.18%98.14M | 30.49%54.27M | 318.52%99.24M | 7.34%62.15M | 120.28%74.25M | 1,254.64%41.59M | -144.64%-45.42M |
Net profit | 185.78%240.36M | 8.16%328.43M | -23.87%280.05M | -59.76%228.48M | -72.28%84.11M | 219.51%303.63M | 689.88%367.86M | 1,008.99%567.79M | 213.48%303.37M | -164.78%-254.07M |
Net profit from continuing operation | 185.78%240.36M | 8.16%328.43M | -23.87%280.05M | -59.76%228.48M | -72.28%84.11M | 219.51%303.63M | 689.88%367.86M | 1,008.99%567.79M | 213.48%303.37M | -164.78%-254.07M |
Less:Minority Profit | -18.05%46.24M | 4.60%95.28M | 15.90%109.71M | 17.78%106.33M | 29.30%56.43M | 16.01%91.09M | 10.27%94.66M | 2.25%90.27M | -24.73%43.64M | -11.59%78.52M |
Net profit of parent company owners | 601.27%194.12M | 9.69%233.15M | -37.65%170.34M | -74.42%122.16M | -89.34%27.68M | 163.91%212.54M | 284.33%273.2M | 416.76%477.52M | 179.84%259.73M | -209.64%-332.59M |
Earning per share | ||||||||||
Basic earning per share | 598.94%0.0657 | 14.29%0.08 | -33.33%0.06 | -75.00%0.04 | -89.32%0.0094 | 163.64%0.07 | 280.00%0.09 | 420.00%0.16 | 179.85%0.088 | -210.00%-0.11 |
Diluted earning per share | 598.94%0.0657 | 14.29%0.08 | -33.33%0.06 | -75.00%0.04 | -89.32%0.0094 | 163.64%0.07 | 280.00%0.09 | 420.00%0.16 | 179.85%0.088 | -210.00%-0.11 |
Other composite income | -89.75%-26.84M | 338.69%99.57M | 141.80%18.99M | 100.78%377.18K | 14.63%-14.15M | -699.98%-41.72M | -669.89%-45.44M | -1,433.35%-48.18M | -266.35%-16.57M | -77.77%6.95M |
Other composite income of parent company owners | -82.07%-27.98M | 330.38%95.17M | 134.58%15.86M | 96.39%-1.73M | 7.96%-15.37M | -552.20%-41.31M | -555.76%-45.86M | -1,150.78%-47.92M | -255.20%-16.7M | -72.73%9.14M |
Other composite income of minority owners | -6.67%1.14M | 1,182.33%4.4M | 638.46%3.13M | 906.25%2.11M | 837.50%1.22M | 81.35%-406.91K | 120.31%424.47K | 72.41%-261.21K | 116.33%130.61K | 1.64%-2.18M |
Total composite income | 205.19%213.52M | 63.41%428M | -7.25%299.04M | -55.96%228.86M | -75.61%69.96M | 205.99%261.92M | 692.81%322.42M | 982.93%519.61M | 211.43%286.81M | -158.36%-247.12M |
Total composite income of parent company owners | 1,249.46%166.13M | 91.73%328.32M | -18.10%186.2M | -71.97%120.43M | -94.93%12.31M | 152.94%171.24M | 264.56%227.33M | 393.86%429.6M | 177.26%243.03M | -196.02%-323.46M |
Total composite income of minority owners | -17.80%47.39M | 9.92%99.68M | 18.67%112.85M | 20.47%108.43M | 31.71%57.65M | 18.79%90.68M | 13.53%95.09M | 3.06%90.01M | -23.45%43.77M | -11.85%76.34M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.